

10 December 2025

Futura Medical plc
("Futura", "the Group" or the "Company")

Patent notice of allowance granted for MED3000 (Eroxon) in China

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that it has been granted notice of allowance of its patent which will provide protection for Eroxon® until 2040 in China.

The prevalence of erectile dysfunction in the 700 million adult males in China is estimated to be approximately 50%, which represents a considerable commercial opportunity.

This allowance adds to the Company's existing protection in Europe, Hong Kong, Taiwan and the US, further consolidating its global IP. Other applications in additional markets remain pending. In addition, Futura Medical is planning to extend its IP protection in China by filing a divisional patent in early 2026.

Alex Duggan, CEO of Futura, commented: *"The grant of this patent in China will mark an important milestone for Futura in one of the largest Erectile Dysfunction markets globally. We now have an enhanced competitive position which supports our commercial strategy as we actively seek partners in this market. We look forward to updating the market on progress in due course."*

Contacts:

Futura Medical plc	Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO	investor.relations@futura-medical.com +44 (0)1483 685 670 www.futura-medical.com
Panmure Liberum Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance)	+44 (0)20 3100 2000
Turner Pope Investments (TPI) Ltd - Broker	Guy McDougall, Andrew Thacker	+44 (0) 20 3657 0050
Alma Strategic Communications	Rebecca Sanders-Hewett, Sam Modlin, Emma Thompson	+44 (0)20 3405 0205 futura@almastrategic.com

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.

Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.

WSD4000 is a topical treatment designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCPKCBDKBDBDBK